← Leaderboards
Milton L. Brown
University Of Virginia Charlottesville
$3,653,693
Attributed
$4,074,235
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $552.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,074,235 · 6
By mechanism
R01$1,690,019 · 1
U19$1,054,558 · 1
U01$552,787 · 1
T32$326,742 · 1
R43$288,297 · 1
P30$161,832 · 1
Top collaborators
- Vidya Kumar1 shared
- Fabio Cohen Tucci1 shared
Most similar at University Of Virginia Charlottesville
Same institution · by research overlap
- Edward Perez-Reyes$8,746,219
- Mark Douglas Okusa$24,807,098
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoPharmaceutical PreparationsToxic EffectLinkAnalogIn VitroDesignTrainingCessation Of LifeTumorGrantMindEvaluationResearch PersonnelCancer CellDoseCancer Cell LineMonitorPharmaceutical ChemistryMalignant NeoplasmsMolecularAmericanDrug DevelopmentAcute
Grant awards (21)
Development of YK-4-250, a radiation mitigator of GI-ARS$552,787
U01 · FY2025 · AI · contact PI
Synthesis and Optimization of Selective alpha4beta2 Neuronal nAChR Desensitizers$231,457
U19 · FY2014 · DA · contact PI
Novel anti-metastasis agents for triple negative breast cancer$288,297
R43 · FY2013 · CA
Synthesis and Optimization of Selective alpha4beta2 Neuronal nAChR Desensitizers$225,513
U19 · FY2013 · DA · contact PI
Synthesis and Optimization of Selective alpha4beta2 Neuronal nAChR Desensitizers$235,302
U19 · FY2012 · DA · contact PI
Synthesis and Optimization of Selective alpha4beta2 Neuronal nAChR Desensitizers$237,669
U19 · FY2011 · DA · contact PI
Synthesis and Optimization of Selective alpha4beta2 Neuronal nAChR Desensitizers$124,617
U19 · FY2010 · DA · contact PI
Molecular Assessment & Preclinical Studies$49,091
P30 · FY2010 · CA · contact PI
Clinical Pharmacology Training Grant$83,374
T32 · FY2009 · GM · contact PI
Molecular Assessment & Preclinical Studies$50,021
P30 · FY2009 · CA · contact PI
Sodium Channel Blockers as Inhibitors of Prostate Cancer$328,773
R01 · FY2008 · CA · contact PI
Clinical Pharmacology Training Grant$119,634
T32 · FY2008 · GM · contact PI
Molecular Assessment & Preclinical Studies$25,088
P30 · FY2008 · CA · contact PI
Sodium Channel Blockers as Inhibitors of Prostate Cancer$325,517
R01 · FY2007 · CA · contact PI
Clinical Pharmacology Training Grant$123,734
T32 · FY2007 · GM · contact PI
Molecular Assessment & Preclinical Studies$25,088
P30 · FY2007 · CA · contact PI
Sodium Channel Blockers as Inhibitors of Prostate Cancer$275,034
R01 · FY2006 · CA · contact PI
Sodium Channel Blockers as Inhibitors of Prostate Cancer$84,706
R01 · FY2006 · CA · contact PI
Molecular Assessment & Preclinical Studies$12,544
P30 · FY2006 · CA · contact PI
Sodium Channel Blockers as Inhibitors of Prostate Cancer$318,593
R01 · FY2005 · CA
Sodium Channel Blockers as Inhibitors of Prostate Cancer$357,396
R01 · FY2004 · CA